Specialty Pharmacy

Steven Pipe, MD, highlights the growing importance of pharmacists in hemophilia care as new therapies expand treatment complexity and require specialized expertise.

Ron Lanton explains that increased pharmaceutical tariffs could drive up costs, reduce margins, and strain pharmacy supply chains, with few mitigation options available.

The pharmaceutical giant will reportedly lower its drug prices to align with most-favored-nation status.

Ron Lanton advises pharmacies to maintain compliance, explore contingency options, and stay engaged with policymakers during the government shutdown.

A retrospective analysis found no associations between lipid parameters and the success of blood stem cell mobilization in a cohort of healthy donors.

Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.

The angiopoietin-like-3-targeting treatment received an expanded indication for individuals aged 1 through 5 years, building on earlier approvals in older populations.

In chronic kidney disease (CKD), SDMA showed a stronger connection to vascular health compared with ADMA.

In an announcement at the White House, Pfizer said it will reduce drug prices in the United States to match those of other countries.

AMT-130 demonstrates meaningful reductions in disease progression in the rare and chronic Huntington disease.

The new formulation of intravenous immunoglobulin (IVIG) provides patients another option to help reduce the incidence of severe bacterial infections.

A meta-analysis found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce sustained reductions across lipid biomarkers, including low-density lipoprotein cholesterol (LDL-C).

The FDA linked cerebral folate deficiency to developmental delays with autistic features, although research remains ongoing.

The indication is for the treatment of adult and pediatric patients who weigh at least 30 kg.

Guselkumab becomes the first and only IL-23 inhibitor with a fully subcutaneous induction regimen for adults with ulcerative colitis.

Participating in a pharmacist-led secondary intervention clinic helped achieve large reductions in cholesterol levels among patients who have experienced an acute coronary syndrome.

Bumetanide nasal spray provides patients with edema an alternative to burdensome oral or intravenous diuretic options.

A series of PCSK9 inhibitors were found to be tolerable and effective at reducing low-density lipoprotein cholesterol in solid organ transplant recipients.

Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.

Experts gathered to discuss the critical need for real-time learning, multidisciplinary collaboration, and comprehensive patient and family support to address unforeseen complications in gene therapy.

Speakers at an ASTCT Gene Therapy Summit highlighted novel conditioning approaches without the use of busulfan, which can cause toxic effects in patients with hematologic malignancies.

Experts at the ASTCT Gene Therapy Summit discussed the multifaceted nature of the gene therapy process for patients with sickle cell disease.

Both cemdisiran alone and combined with pozelimab improved the Myasthenia Gravis Activities of Daily Living score in patients with generalized myasthenia gravis.

Pharmacies increasingly dispense buprenorphine, enhancing access to opioid addiction treatment while embracing AI and telepharmacy innovations for better care.

Results from the phase 3 SAPPHIRE trial show significant improvements in motor function in children and adults with spinal muscular atrophy.

If long-term efficacy results are positive, metformin can become an accessible, affordable treatment option for autosomal dominant polycystic kidney disease (ADPKD).

A systematic review and meta-analysis revealed key insights into lipid parameters in patients with systemic sclerosis.